A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Fatty liver disease
FATTY LIVER DISEASE
NewsExposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- Don’t let living with MASH stop you from your New Year’s goals
- Frequent bile acid level checks urged to predict stillbirth in severe ICP
- Wegovy cleared in Canada to treat fatty liver disease MASH
- Medications known as IBATIs are safe, effective in Alagille: Analysis
- New rapid test could accelerate hepatitis C diagnosis and treatment